PBH Stock Recent News
PBH LATEST HEADLINES
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.04 per share a year ago.
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.
Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q2 2024 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Phil Terpolilli - CFA Ron Lombardi - President and CEO Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Co Susan Anderson - Canaccord Genuity Jon Andersen - William Blair Keonhee Kim - Morningstar Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Prestige Consumer Healthcare Earnings Conference Call.
Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Down -11.27% in 4 Weeks, Here's Why You Should You Buy the Dip in Prestige Consumer Healthcare (PBH)
The heavy selling pressure might have exhausted for Prestige Consumer Healthcare (PBH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.